NOS3 and metabolic disease: DXT-M achieved this by modulating a network of metabolites (including citrate, taurine, glutamate, alanine, and others), which interact with targets of hepatic drug-metabolising enzymes, NOS3, and LDHA, thereby correcting endogenous metabolic disorders through intrinsic target molecules.